Hyruan Plus (sodium hyaluronate) / LG Chem - LARVOL DELTA

Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Seoul National University Hospital | N=26 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Otorhinolaryngology

Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (clinicaltrials.gov) - P1/2 | N=26 | Not yet recruiting | Sponsor: Seoul National University Hospital | Trial primary completion date: Feb 2026 ➔ Dec 2026

Trial primary completion date • Otorhinolaryngology

Verification of the Efficacy/safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (clinicaltrials.gov) - P1/2 | N=26 | Not yet recruiting | Sponsor: Seoul National University Hospital | Initiation date: Feb 2025 ➔ Sep 2025

Trial initiation date • Otorhinolaryngology

Hyaluronic Acid Viscosupplement Modulates Inflammatory Mediators in Chondrocyte and Macrophage Coculture via MAPK and NF-κB Signaling Pathways. (PubMed, ACS Omega) - "In this study, we examined the impact of hyaluronic acid (HA) viscosupplement, particularly Hyruan Plus, on chondrocytes and macrophages...HA also reduced the expression level of inflammatory cytokines such as IL-1β, TNF-α, and IL-6 in macrophages, and HA exerted an overall protective effect by partially suppressing the MAPK pathway in chondrocytes and p65/NF-κB signaling in macrophages. Therefore, HA shows potential as a viscosupplement for treating arthritic joints."

Journal • Immunology • Inflammation • Musculoskeletal Diseases • Osteoarthritis • Pain • Rheumatology • ACAN • IFNG • IL1B • IL6 • MMP13 • TNFA

No Difference Between One-shot Co-injection of Corticosteroids and Hyaluronic Acid in a Three-injection Regimen for Knee Osteoarthritis: A Randomized, Double-blind Trial. (PubMed, Clin Orthop Relat Res) - "We found that a single co-injection of corticosteroids along with HA did not confer any additional benefit regarding patient-reported outcomes or physical function compared with a three-injection regimen of HA. Therefore, we do not recommend a one-shot co-injection of corticosteroids alongside the three-injection regimen of HA for patients with knee OA, and because prior research found HA to be ineffective, HA should not be used with or without corticosteroids for patients with knee OA."

Clinical • Journal • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain • Rheumatology

Effects and Safety of Intra-Articular Sodium Hyaluronate Injection for the Treatment of Ankle Osteoarthritis: A Prospective Clinical Trial. (PubMed, J Foot Ankle Surg) - "3 weekly hyaluronate injections (2 mL Hyruan Plus®) were administered...This study suggests that 3 weekly intra-articular hyaluronate injections can be performed safely to reduce pain and improve function without serious complications in patients with early or intermediate-grade ankle osteoarthritis when patients inadequately respond to medication. Larger controlled studies are needed to clarify the effects of hyaluronate injection and identify patients who can benefit most from hyaluronate injection."

Clinical • Journal • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Yifan Pharmaceutical's application for cross-linked sodium hyaluronate injection has been accepted for use in knee osteoarthritis [Google translation] (Eastmoney.com) - "On July 23, Yifan Pharmaceutical An announcement was made that the listing application for cross-linked sodium hyaluronate injection submitted by a wholly-owned subsidiary was accepted by the State Food and Drug Administration. The drug is used for the treatment of knee osteoarthritis...Yifan Pharmaceutical stated that if Hyruan ONE is successfully approved for listing in China, a single injection can achieve the efficacy of at least 3 injections of other sodium hyaluronate injections."

Non-US regulatory • CNS Disorders • Osteoarthritis • Pain

Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - P2; N=115; Completed; Sponsor: Dong-A ST Co., Ltd.; Recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Pilot Study to Evaluate the Efficacy of Polynucleotide Sodium Compared to Sodium Hyaluronate and Crosslinked Sodium Hyaluronate in Patients with Knee Osteoarthritis. (PubMed, J Clin Med) - "In this pilot study, we aimed to compare polynucleotide sodium (Conjuran) with sodium hyaluronate (Hyruan Plus) and 1,4-butanediol diglycidyl ether-crosslinked sodium hyaluronate (Synovian) in terms of analgesic efficacy after intraarticular injection in patients with knee osteoarthritis...No adverse events occurred. In conclusion, polynucleotide sodium could effectively reduce weight-bearing pain in the patients with knee osteoarthritis compared to standard hyaluronic acid viscosupplementation."

Clinical • Journal • Immunology • Osteoarthritis • Pain • Rheumatology